Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Jane Street Group LLC

Jane Street Group LLC reduced its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 59.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,383 shares of the company's stock after selling 86,001 shares during the period. Jane Street Group LLC owned about 0.21% of Castle Biosciences worth $1,583,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. Northern Trust Corp raised its position in Castle Biosciences by 8.7% during the fourth quarter. Northern Trust Corp now owns 284,587 shares of the company's stock worth $7,584,000 after acquiring an additional 22,657 shares during the period. Tudor Investment Corp ET AL raised its position in Castle Biosciences by 41.6% during the fourth quarter. Tudor Investment Corp ET AL now owns 70,076 shares of the company's stock worth $1,868,000 after acquiring an additional 20,586 shares during the period. Aquatic Capital Management LLC acquired a new position in Castle Biosciences during the fourth quarter worth $539,000. Birchview Capital LP raised its position in Castle Biosciences by 34.5% during the fourth quarter. Birchview Capital LP now owns 78,000 shares of the company's stock worth $2,079,000 after acquiring an additional 20,000 shares during the period. Finally, Nebula Research & Development LLC acquired a new position in Castle Biosciences during the fourth quarter worth $711,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Castle Biosciences Trading Up 1.3%

Shares of CSTL traded up $0.21 during mid-day trading on Friday, reaching $16.10. The stock had a trading volume of 287,423 shares, compared to its average volume of 406,893. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. Castle Biosciences, Inc. has a 52-week low of $15.66 and a 52-week high of $35.84. The business's fifty day moving average is $19.14 and its 200 day moving average is $24.47. The firm has a market cap of $464.84 million, a price-to-earnings ratio of 80.50 and a beta of 1.19.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.12). Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The firm had revenue of $87.99 million during the quarter, compared to analysts' expectations of $80.40 million. On average, sell-side analysts predict that Castle Biosciences, Inc. will post 0.44 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on CSTL. Guggenheim set a $30.00 target price on shares of Castle Biosciences and gave the company a "buy" rating in a research report on Friday, March 28th. Canaccord Genuity Group reduced their target price on shares of Castle Biosciences from $42.00 to $37.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Lake Street Capital reduced their target price on shares of Castle Biosciences from $40.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Robert W. Baird increased their target price on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Finally, Scotiabank reduced their target price on shares of Castle Biosciences from $44.00 to $40.00 and set a "sector outperform" rating for the company in a research report on Wednesday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $37.00.

Insiders Place Their Bets

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,130 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $19.52, for a total transaction of $41,577.60. Following the completion of the transaction, the insider now owns 78,335 shares of the company's stock, valued at $1,529,099.20. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 27,454 shares of company stock valued at $553,030 over the last 90 days. 6.50% of the stock is owned by company insiders.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.